ClinicalTrials.gg
RecruitingNCT05515770ImPrepCabUpdated Oct 8, 2024

The Implementation of Pre-exposure Prophylaxis of Injectable Cabotegravir

A Phase 3 interventional study of Cabotegravir Injection in HIV Infections, sponsored by Evandro Chagas National Institute of Infectious Disease. Recruiting at 1 site in Brazil. Open to male participants aged 18 Years to 30 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Evandro Chagas National Institute of Infectious Disease · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Not applicable
Ages
18 Years to 30 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Planned enrollment
5th of 36
1,200 · median 200
Started
2022
with 2 others
Phase 3
12 of 36
2 open now
Primary completion
2025-10
later than 5 of 12 live
Registered
27th of 36
by date
Lead sponsor
1 of 36
Evandro Chagas National Institute of Infectious Disease

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 5th largest by planned enrollment, is one of 3 that started in 2022, is one of 12 in phase 3, reaches primary completion later than 5 of the 12 other live ones, and was the 27th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 30 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

Although CAB LA PrEP has been proven efficacious in blinded randomized controlled clinical trials, additional research is needed to evaluate effectiveness in real world settings as well as to identify effective implementation strategies. The proposed implementation study will assess the safety and effectiveness of open label CAB LA PrEP when offered at public health facilities to cisgender men and transgender or gender non-binary individuals who have sex with persons assigned male at birth. The study will also evaluate two nested implementation strategies, an mHealth education and decision support tool and a WhatsApp injection appointment reminder. The study will also assess overall facilitators and barriers to integrating CAB LA into existing oral PrEP services.

Read the detailed description

HIV Pre-Exposure Prophylaxis in Latin America: Results from randomized clinical trials and observational studies have proven that oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis (PrEP) is protective against HIV acquisition. This protection has been confirmed to be both effective and safe across all types of exposures, sexes and gender identities, and dosing regimens. PrEP is now recommended as part of the standard prevention regimen by the World Health Organization (WHO) for individuals at substantial risk of HIV infection. Increasing PrEP access is a priority in Latin America, where several countries have recorded a rising HIV infection incidence, particularly among men who have sex with men (MSM).

In 2020, there were an estimated 930,000 people in Brazil living with HIV (PLWH). Recent studies estimate an HIV prevalence among Brazilian MSM reaching approximately 23% and rates among transgender women (TGW) surpassing 30% in some cities. Young MSM are among the few populations with increasing numbers of new HIV infections in Brazil, where HIV incidence has stabilized in overall population. PrEP in Brazil is freely available through the national Public Health System. As of May 2022, there were 424 healthcare centers across all Brazilian states providing PrEP to approximately 343,000 individuals. Although over 80% of current PrEP users in Brazil are MSM, PrEP utilization remains well below the 2018 estimate of 66,120 Brazilian MSM aged 15-64 years who were eligible for and willing to use PrEP. This number is likely to be even higher with 2021 population estimates. Among more than 57,000 individuals that initiated PrEP in Brazil, approximately 43% discontinued its use. PrEP discontinuation was common among MSM (\~40%) and TGW (over 50%).

Tenofovir-based oral PrEP has been effective in dramatically reducing population-level HIV incidence in multiple districts, including London, San Francisco, New South Wales, and in rural Kenya and Ugand. Despite these successes, PrEP has not decreased HIV incidence equally, particularly among the most at-risk populations (women, youth, racial and ethnic minority MSM, and TGW), due to user adherence challenges. PrEP Brasil, the Brazilian daily oral PrEP demonstration study, identified that 74% of overall participants had protective drug levels. Nevertheless, young participants and TGW had decreasing rates of protective drug concentrations throughout the study. In addition, data from the ImPrEP study, the largest PrEP demonstration study in Latin America with the goal of evaluating the feasibility of same-day PrEP implementation to MSM and transgender women in the context of the Public Health Systems of Brazil, Mexico, and Peru, identified lower PrEP adherence among transgender woman and individuals younger than 24 years of age.

To realize PrEP benefits, individuals need to both initiate PrEP and remain on PrEP during periods at-risk. In multiple studies, reasons for stopping or never initiating PrEP include, in addition to challenges accessing the medication, low self-perceived risk, concerns about medication side effects or a desire not to take a daily pill, stigma, or competing life events. Long-acting PrEP agents have the potential to address some of these concerns by providing consistent protection through infrequent, discrete administration, avoiding relying on adherence to a daily oral regimen and the need for disclosure with sex partners and acquaintances.

Long Acting Cabotegravir for Prevention: Long-acting injectable cabotegravir (CAB-LA) is a novel integrase strand-transfer inhibitor (INSTI). Two large randomized controlled trials (RCTs), known as HIV Prevention Trials Network (HPTN) Study 083 and HPTN Study 084, have demonstrated the effectiveness of injectable cabotegravir when compared to oral tenofovir-disoproxil-fumarate/emtricitabine (TDF/FTC) PrEP.

HPTN 083 was a double-blind double-dummy RCT which assessed the effectiveness of every-8-week dosing of cabotegravir for PrEP compared to oral TDF/FTC PrEP among cisgender men and TGW at 43 sites in the United States, Latin America, Asia, and Africa using a non-inferiority study design. Overall, 4,566 participants, of whom 12.5% were TGW, were assigned 1:1 to injectable cabotegravir given every 8 weeks or daily oral TDF/FTC PrEP and were followed for 153 weeks during the blinded phase of the study. The blinded portion of the study was stopped early for efficacy, with injectable cabotegravir demonstrating statistical superiority over TDF/FTC with a hazard ratio (HR) of 0.34 for HIV incidence when compared to TDF/FTC [95% confidence interval (CI)=0.18-0.62]. Evidence of post-enrollment HIV infection was identified in 51 participants, with only 12 of the cases occurring in the cabotegravir group. When examining sub-groups, the magnitude and direction of the effectiveness of cabotegravir was preserved among populations who have historically experienced greater adherence challenges with TDF/FTC PrEP, including among youth, TGW, and U.S. Black participants.

Updated results including incident HIV infections for the Year 1 unblinded period show 11 new incident HIV infections in the CAB arm and 31 in the TDF/FTC arm, maintaining a HR of 0.34, with incidence rates in both arms showing more than 1 ½ fold higher in the unblinded period compared to the blinded period, with no new safety concerns identified. PrEP adherence declined in both arms over time. In the TDF/FTC arm, adherence decreased from 73% in the blinded period to 59% the Year 1 unblinded period. In the CAB arm, injection "coverage" declined from 91.5% during the blinded study period to 79.9% during the Year 1 unblinded period.

An important characteristic of ARV-based PrEP regimens is how long the drug persists after final administration (i.e., the tail phase of the drug). It was initially thought that the pharmacokinetic tail could create a period of vulnerability in persons who acquire HIV infection, allowing for emergence of drug-resistant strains (33,34). However, based on the current data, it seems very unlikely that this is a period of vulnerability as no incident infections have happened during the pharmacological tail period in the HTPN 083 trial.

Rare breakthrough infections were observed in HPTN 083, but detection of HIV infection in participants who received CAB PrEP was often delayed using standard HIV testing algorithms. Integrase strand transfer inhibitor (INSTI) resistance-associated mutations (RAMs) were detected in 5 CAB-exposed participants with HIV infection (GenoSure PRIME assay, viral load [VL] ≥500 c/mL); 2 other participants did not have genotyping results since all VLs were \<500 c/mL. In all 7 participants, detection of infection at study sites using rapid tests and antigen/antibody tests was delayed (median 60 days; range 35-117) and all 7 participants received CAB-LA injections after HIV infection had occurred. The use of a single-genome sequencing (SGS) INSTI genotyping assay detected INSTI RAMs in 6/7 participants. The use of an RNA assay with a limit of detection (LOD) of 30 copies/mL detected infection before a major INSTI RAM was detected (4 cases) or before additional major INSTI RAMs accumulated (2 cases). In the last case, this could not be assessed since SGS was not successful before the first site-positive visit. Consistent with newly released CDC guidelines, earlier detection of HIV infection using an HIV RNA assay in the setting of CAB-LA PrEP would allow for earlier antiretroviral therapy (ART) initiation which may reduce the risk of INSTI resistance. The impact of different HIV testing strategies on INSTI resistance in real-world settings is unclear making implementation science projects critical.

Using a similar superiority study design, HPTN 084 enrolled HIV negative cisgender women at risk for HIV infection at 20 sites in 7 countries in sub-Saharan Africa including South Africa, Botswana, Eswatini, Zimbabwe, Malawi, Kenya and Uganda. Overall, 3,223 cisgender women were enrolled, with 57% of participants 18-25 years old. There were 40 confirmed HIV infections observed over 3892 person-years of follow up. The overall HIV incidence among all study participants was 1%, suggesting that both products were highly effective in preventing HIV in this population. Four infections were detected in the CAB arm which is equivalent to an incidence of 0.2%, and 36 infections were detected in participants assigned to TDF/FTC which is equivalent to an incidence of 1.85%. No differences in treatment effects were observed in pre-specified sub-group analyses exploring effects by age, BMI, and contraceptive use.

Data from 083 and 084 supported the US Food and Drug Administration regulatory approval of CAB-LA for HIV prevention on December 20, 2021. Subsequently, national regulatory approval for CAB-LA PrEP has been sought in numerous countries, including Brazil.

The ImPrEP Study: ImPrEP is a UNITAID funded, multi-country PrEP implementation project. It is a collaboration between the Oswaldo Cruz Foundation (Fiocruz) and Ministries of Health from Brazil, Peru, and Mexico. One of the ImPrEP components has been a multi-site prospective, open-label demonstration study to assess uptake, acceptability, and feasibility of same-day, daily TDF/FTC oral PrEP among MSM and TGW at substantial risk for HIV acquisition. A total of 28 sites conducted the study, 14 sites in Brazil, 4 in Mexico, and 10 in Peru. Overall, a total of 9,509 participants were enrolled with 26% being young (18-24 years), 73% were non-white, and over 640 (5.6%) participants were TGW. Overall, 68% of participants had long-term engagement; however, younger, less educated participants, TGW and sex workers were significantly less likely to reach long-term engagement.

Although HIV incidence during the study was relatively low (0.82/100 person-years), it was higher among non-white, younger (18-24 years) and TGW participants. These disproportionately worse outcomes highlight that PrEP agents not requiring daily or planned oral dosing could increase effective PrEP use among these most vulnerable populations. It is reassuring that injectable cabotegravir has demonstrated comparable effectiveness among youth, Black MSM, and TGW in clinical trials. However, advantages in bypassing daily adherence behavior may not be realized if individuals cannot access injectable PrEP or do not return for repeat injections. Additional data from injectable PrEP service delivery in real-world settings will be needed to support roll-out and national program decisions to include CAB LA PrEP as part of prevention services.

Person-centered HIV Prevention: At the core of person-centered HIV prevention is the acknowledgement that people are best placed to decide which prevention methods are right for them and that their preference may change over the course of their life. Person-centered care emphasizes meeting an individual's sexual preferences, needs, and goals, using person-centered counseling approaches, such as shared decision-making. In a counseling visit utilizing shared decision-making, the individual is recognized as the expert regarding their lived experience, life situations, needs, and preferences for sexual health prevention and care. The conclusion of such a counseling conversation may include patients choosing not to use a prevention method or discontinuation of a more effective method for a less effective method (or no method at all). Central to a people-centered approach to HIV prevention is effectively communicating information about the advantages and disadvantages of available methods and about product characteristics to facilitate informed decision making. A people-centered approach also supports adherence, once an HIV prevention method has been chosen, in ways which will be experienced as supportive and useful by the method user.

Implementation Research is Needed to Prepare for Scale-up of CAB-LA PrEP: Now that the efficacy of CAB-LA PrEP has been proven in large clinical trials, implementation studies must explore how to best integrate its delivery into existing PrEP services in 'real world' settings. Implementation studies provide crucial information about how interventions, proven efficacious under randomized clinical trial conditions, can be optimized for delivery within routine service contexts. Implementation research provides an opportunity to identify implementation barriers and to maximize the feasibility and acceptability of intervention delivery as well as intervention effectiveness.

The investigators are proposing a CAB-LA implementation-effectiveness research study (hybrid Type 2) that leverages the impact of the current ImPrEP project in Brazil to generate critical evidence about the feasibility, acceptability, and effectiveness of incorporating CAB-LA PrEP into existing services for oral PrEP. This implementation project is fully grounded in the principles of people-centered care, with a focus on respect for participant's preference and expressed needs. Study results will inform global guideline recommendations, regional and national policy development, and program implementation guidance for Brazil and other low and middle-income countries (LMIC).

In the field of contraception, increased availability of method options and informed decision-making about method choice has improved uptake and persistence of the contraceptive methods used. It is likely that expanding method options for HIV prevention will similarly improve uptake and persistence. However, informed decision-making requires user understanding of how methods must be used, potential side effects, and effectiveness. Although health worker counseling plays a crucial role in providing patients with information about different methods, mobile health (mHealth) has great potential to provide valuable additional educational support. For example, decision support tools have been shown to be both acceptable and effective in guiding women's contraceptive decisions. The investigators will develop and test a similar mHealth education and decision support tool for use in MSM, non-binary and transgender populations.

Adherence to the CAB LA injection schedule (at 1 month for a second dose, and every 2 months thereafter) will be crucial to preventing HIV acquisition. Although the results of HPTN 083 and 084 demonstrated that overall, participants had better adherence to clinic visits for their CAB LA injections than for daily oral PrEP, additional support for maintaining adherence to the CAB LA injection clinic visits is needed for some users. In a randomized controlled trial, interactive short message service (SMS)-based support improved daily oral PrEP persistence (80% vs. 57% at 36 weeks, p\<0.01) when compared to standard of care among diverse young MSM at risk for HIV acquisition in the US. In the current study, The investigators will test the impact of WhatsApp appointment reminders on participant adherence and continuation of CAB-LA PrEP.

Finally, this implementation research study will include an exploration of the best, acceptable HIV testing strategy and algorithm for use with CAB LA PrEP. A key challenge with the implementation of injectable cabotegravir as PrEP is its impact on diagnosis of breakthrough HIV infections. Detection of HIV infection at study sites was delayed in participants in both HPTN 083 and 084, illustrating the challenge of using conventional testing approaches to screen for HIV infection in studies using potent, long-acting PrEP agents. With CAB-LA, the result of delayed diagnosis may contribute to the development of resistance associated mutations that would be expected to confer reduced susceptibility to integrase inhibitors. The use of an HIV RNA assay for screening could possibly detect these infections earlier, prompting earlier ART initiation and preventing emergence of HIV resistance. Nevertheless, viral load (VL) testing is expensive and could cause implementation of cabotegravir-based PrEP to remain limited in LMICs should these testing requirements be adopted by regulatory agencies and guideline panels. Early detection of HIV infection and prompt ART initiation could improve clinical outcomes in persons who become infected despite CAB-LA prophylaxis. In addition to HIV rapid tests this study will incorporate the use of point-of-care VL testing with GeneXpert for VL to identify HIV infection not detectable with the HIV rapid tests at enrollment. The use of this technology will enable participants to receive VL results and, if negative, receive a same-day CAB LA injection. The use of non-INSTI ART to treat people who acquire HIV while taking injectable CAB may be an option.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Cabotegravir
  • pre exposure prophylaxis
04

Who can participate

Ages eligible
18 Years to 30 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cisgender men, non-binary (assigned as male at birth) or transgender women and men
  2. Report having anal sex with a person assigned male at birth in the last six months (Persons born female having sex only with other persons born female are excluded)
  3. Age 18-30 years
  4. Seek a study clinic looking for PrEP
  5. CAB LA and TDF/FTC PrEP naïve
  6. Willing and able to provide written and adhere to the study requirements
  7. Non-reactive / negative test results, including both HIV rapid tests and an undetectable HIV RNA at enrollment for individuals choosing injectable CAB-LA.
  8. No report of hepatic dysfunction. Candidates reporting liver disease will have their enrollment visit postponed until laboratory results of liver function are available. Individuals with >=5x , OR ALT>=3xULN and >=1.5xULN will be excluded. See section 7 (Study Procedures - Enrollment visit).
  9. Willing to undergo all required study procedures.

Exclusion criteria

Exclusion Criteria:

  1. One or more reactive or positive test result at enrollment visit, even if HIV infection is not confirmed.
  2. Currently participating in interventional trial of PrEP agents, HIV vaccine trial or experimental medication.
  3. Positive pregnancy test, breastfeeding, or intention to become pregnant at enrolment (for transgender men).
  4. Prior participation in studies with Cabotegravir.
  5. A history or presence of allergy to the study drug components.
  6. Past participation in HIV vaccine trial. An exception will be made for participants that can provide documentation of receipt of placebo (not active arm).
  7. Plan to relocate out of the area during the study period.
  8. Surgically placed or injected buttock implants or fillers, per self-report.
  9. Has a dermatological/inflammatory skin condition overlying the buttock region which in the opinion of the study investigator, in consultation with the Clinical Study Coordination (CSC), may interfere with interpretation of injection site reactions.
  10. Active or planned use of co-administered for which significant decreases in Cabotegravir plasma concentrations may occur due uridine diphosphate glucuronosyltransferase (UGT1A1):

    • Anticonvulsants: Carbamazepine, Oxcarbazepine, Phenobarbital, Phenytoin
    • Antimycobacterials: Rifampin, Rifapentine *Any prohibited medications that decrease CAB concentrations should be discontinued for a minimum of four weeks or a minimum of three half-lives (whichever is longer) prior to the first dose.
  11. Current or anticipated need for chronic systemic anticoagulation or a history of known or suspected bleeding disorder, including a history of prolonged bleeding.
  12. History of severe hepatic impairment (including but not limited to a history of liver failure or hospitalization for liver disease, a history of hepatocellular carcinoma or near liver transplant).
  13. Individuals with advanced .
  14. Other medical conditions that, in the opinion of the study investigator, would interfere with the conduct of the study (e.g., provided by self-report, or found upon medical).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Injectable Cabitegravir

    Participants that are interested in Cab long action injectable

    Drug: Cabotegravir Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incident HIV infection

    Among individuals who test positive on HIV rapid test, midpoint between last negative HIV rapid test and first HIV positive rapid test

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ
    Rio De Janeiro, 21040-360, Brazil
    Recruiting
    • Thiago Torres, Pharm D, PhD · Contact+55213865-9573
    • Brenda Hoagland, MD, PhD · Contact+55213865-9122
    • Beatriz Grinsztejn, MD, PhD · Principal investigator
    • Valdilea Veloso, MD, PhD · Sub investigator
    • Brenda Hoagland, MD, PhD · Sub investigator
    • Sandra Wagner Cardoso, MD, PhD · Sub investigator
    • Emilia Jalil, MD, PhD · Sub investigator
    • Thiago Torres, Pharm D, PhD · Sub investigator
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Oct 2025, 37 months after the start.

Of 44 non-industry phase 3 interventional studies under HIV Infections, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 37 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 25, 2022
StartActual
Sep 20, 2022
Primary completionEst.
Oct 2025
CompletionEst.
Feb 2026
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05515770
Lead sponsor
Evandro Chagas National Institute of Infectious Disease
Collaborators
Beatriz Grinsztejn, Thiago Torres, Valdilea Gonçalves, Brenda Hoagland
Responsible party
Raquel Malaguthi de Souza (Beatriz Grinsztejn, MD, PhD, Evandro Chagas National Institute of Infectious Disease) — Principal investigator
First posted
Aug 25, 2022
Start date
Sep 20, 2022
Primary completion
Oct 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
Oct 8, 2024

Study contacts

Thiago Torres, Pharm D, PhD
Contact
thiago.torres@ini.fiocruz.br
+55213865-9573
Brenda Hoagland, MD, PhD
Contact
brenda.hoagland@ini.fiocruz.br
+55213865-9122
Beatriz Grinsztejn, MD, PhD
principal investigator · Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ
Valdilea Veloso, MD, PhD
study director · Instituto Nacional de Infectologia Evandro Chagas/ FIOCRUZ

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion